Pharmachronicles

Top Menu

  • Home
  • Our Blog
  • Contact Us

Main Menu

  • Home Page
  • STUDENTS ZONE
  • Syllabus
  • Seminars & conferences
  • Online classes
    • Register
Sign in / Join

Login

Welcome! Login in to your account
Lost your password?

Lost Password

Back to login
  • Home
  • Our Blog
  • Contact Us

logo

  • Home Page
  • STUDENTS ZONE
  • Syllabus
  • Seminars & conferences
  • Online classes
    • Register
  • Resurgence of COVID-19 in Hong Kong and Singapore: A New Wave Driven by Waning Immunity and Emerging Variants

  • How Pharmacists Support Chronic Disease Management in the Community

  • OTC Medications: Safe Use, Common Mistakes, and Pharmacist Guidance

  • Pharmacovigilance Explained: Why Reporting Adverse Drug Reactions Saves Lives

  • Indian CDMOs Gain Global Momentum Amid Pharma’s Shift from China

Medical & Health
Home›Medical & Health›Clinical trial of the HIV vaccine proves safe in human use.

Clinical trial of the HIV vaccine proves safe in human use.

By Ramoju kishore kumar
July 7, 2018
952
0
Share:

 

Based on the results from this phase 1/2a clinical trial that involved nearly 400 healthy adults, a phase 2b trial has been initiated in southern Africa to determine the safety and efficacy of the HIV-1 vaccine candidate in 2,600 women at risk for acquiring HIV. This is one of only five experimental HIV-1 vaccine concepts that have progressed to efficacy trials in humans in the 35 years of the global HIV/AIDS epidemic.

Previous HIV-1 vaccine candidates have typically been limited to specific regions of the world. The experimental regimens tested in this study are based on ‘mosaic’ vaccines that take pieces of different HIV viruses and combine them to elicit immune responses against a wide variety of HIV strains.

“These results represent an important milestone. This study demonstrates that the mosaic Ad26 prime, Ad26 plus gp140 boost HIV vaccine candidate induced robust immune responses in humans and monkeys with comparable magnitude, kinetics, phenotype, and durability and also provided 67% protection against viral challenge in monkeys,” says Professor Dan Barouch, Director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center and Professor of Medicine at Harvard Medical School, Boston, USA who led the study.

He adds: “These results should be interpreted cautiously. The challenges in the development of an HIV vaccine are unprecedented, and the ability to induce HIV-specific immune responses does not necessarily indicate that a vaccine will protect humans from HIV infection. We eagerly await the results of the phase 2b efficacy trial called HVTN705, or ‘Imbokodo’, which will determine whether or not this vaccine will protect humans against acquiring HIV.”

Almost 37 million people worldwide are living with HIV/AIDS, with an estimated 1.8 million new cases every year. A safe and effective preventative vaccine is urgently needed to curb the HIV pandemic.

In the 35 years of the HIV epidemic, only four HIV vaccine concepts have been tested in humans, and only one has provided evidence of protection in an efficacy trial — a canarypox vector prime, gp120 boost vaccine regimen tested in the RV144 trial in Thailand lowered the rate of human infection by 31% but the effect was considered too low to advance the vaccine to common use.

A key hurdle to HIV vaccine development has been the lack of direct comparability between clinical trials and pre clinical studies. To address these methodological issues, Barouch and colleagues evaluated the leading mosaic adenovirus serotype 26 (Ad26)-based HIV-1 vaccine candidates in parallel clinical and pre-clinical studies to identify the optimal HIV vaccine regimen to advance into clinical efficacy trials.

The APPROACH trial recruited 393 healthy, HIV-uninfected adults (aged 18-50 years) from 12 clinics in east Africa, South Africa, Thailand, and the USA between February 2015 and October 2015. Volunteers were randomly assigned to receive either one of seven vaccine combinations or a placebo, and were given four vaccinations over the course of 48 weeks.

To stimulate, or ‘prime’, an initial immune response, each volunteer received an intramuscular injection of Ad26.Mos.HIV at the start of the study and again 12 weeks later. The vaccine containing ‘mosaic’ HIV Env/Gag/Pol antigens was created from many HIV strains, delivered using a nonreplicating common-cold virus (Ad26).

To ‘boost’ the level of the body’s immune response, volunteers were given two additional vaccinations at week 24 and 48 using various combinations of Ad26.Mos.HIV or a different vaccine component called Modified Vaccinia Ankara (MVA) with or without two different doses of clade C HIV gp140 envelope protein containing an aluminium adjuvant.

Results showed that all vaccine regimens tested were capable of generating anti-HIV immune responses in healthy individuals and were well tolerated, with similar numbers of local and systemic reactions reported in all groups, most of which were mild-to-moderate in severity. Five participants reported at least one vaccine-related grade 3 adverse event such as abdominal pain and diarrhea, postural dizziness, and back pain. No grade 4 adverse events or deaths were reported.

In a parallel study, the researchers assessed the immunogenicity and protective efficacy of the same Ad26-based mosaic vaccine regimens in 72 rhesus monkeys using a series repeated challenges with simian-human immunodeficiency virus (SHIV) — a virus similar to HIV that infects monkeys.

The Ad26/Ad26 plus gp140 vaccine candidate induced the greatest immune responses in humans and also provided the best protection in monkeys — resulting in complete protection against SHIV infection in two-thirds of the vaccinated animals after six challenges.

The authors note several limitations, including the fact that that the relevance of vaccine protection in rhesus monkeys to clinical efficacy in humans remains unclear. They also note that there is no definitive immunological measurement that is known to predict protection against HIV-1 in humans.

Writing in a linked Comment, Dr George Pavlakis and Dr Barbara Felber from the National Cancer Institute at Frederik, Maryland, USA say: “Efficacy studies are necessary to determine protective ability in humans and also for the discovery of correlates of protection and for determining whether the same or different immune correlates apply for different vaccine regimens. It remains to be determined whether improved efficacy over RV144 will be achieved by either of the present efficacy trials (NCT02968849; NCT03060629). New vaccine concepts and vectors are in development and can progress to efficacy trials, which is an important process since development of an AIDS vaccine remains urgent. Despite unprecedented advances in HIV treatment and prophylaxis, the number of people living with HIV infection continues to increase worldwide. Implementation of even a moderately effective HIV vaccine together with the existing HIV prevention and treatment strategies is expected to contribute greatly to the evolving HIV/AIDS response. It is therefore essential that a commitment to pursue multiple vaccine development strategies continues at all stages.”

This study was funded by Janssen Vaccines & Prevention BV, US National Institutes of Health, Ragon Institute of MGH, MIT and Harvard, Henry M Jackson Foundation for the Advancement of Military Medicine, US Department of Defense, and International AIDS Vaccine Initiative.

TagsAfricaHIVImmunogenicity.
Previous Article

A trial finds new revolution in migraine ...

Next Article

Mens with migraine headache has an elevated ...

0
Shares
  • 0
  • +
  • 0
  • 0
  • 0
  • 0
Avatar photo

Ramoju kishore kumar

Related articles More from author

  • Medical & Health

    Cancer Vaccination Rates Rising Among U.S. Teens From Year To Year

    August 26, 2018
    By Ramoju kishore kumar
  • DiseaseMedical & HealthMedical researchTreatment

    Polycystic ovary syndrome

    June 18, 2019
    By Sundari srinidhi
  • Medical & HealthMedical research

    IMMUNITY

    June 18, 2019
    By Sundari srinidhi
  • Medical & Health

    AIOS releases new guidelines for operation of eye care facilities

    May 16, 2020
    By Pharmachronicles
  • Medical & Health

    EEG Machine to Create Digital Images From Brain Activity

    April 14, 2018
    By Ramoju kishore kumar
  • DiseaseMedical & HealthMedical researchTreatment

    Excess weight and body fat cause cardiovascular disease

    June 18, 2019
    By Ramoju kishore kumar

Leave a reply Cancel reply

You may interested

  • Educational news

    Can a mutation makes the zika virus grew deadlier

  • Treatment

    Failure of the immunotherapy agent in the NSCLC

  • BLOGS

    Cell replacement therapy for parkinson’s disease

  • LATEST REVIEWS

  • TOP REVIEWS

  • Pharmacists are not eligible for certificate program of community health

    0
  • A New Class of Antimicrobials Has Just Been Found in Human Breast Milk Fresh super ...

    0

Timeline

  • May 17, 2025

    Resurgence of COVID-19 in Hong Kong and Singapore: A New Wave Driven by Waning Immunity and Emerging Variants

  • May 9, 2025

    How Pharmacists Support Chronic Disease Management in the Community

  • May 9, 2025

    OTC Medications: Safe Use, Common Mistakes, and Pharmacist Guidance

  • May 7, 2025

    Pharmacovigilance Explained: Why Reporting Adverse Drug Reactions Saves Lives

  • May 6, 2025

    Indian CDMOs Gain Global Momentum Amid Pharma’s Shift from China

Latest Comments

  • Pharmachronicles
    on
    February 27, 2025
    Thank you sir

    Streamlining Salaries through Payment Credit System and Other Benefits for Pharmacy Professionals: Suggestive Measures for PCI ...

  • G Krishna moorthy
    on
    February 1, 2025
    Good 👍 efforts Congratulations Continue your valuable professional services

    Streamlining Salaries through Payment Credit System and Other Benefits for Pharmacy Professionals: Suggestive Measures for PCI ...

  • Aarati sonawane
    on
    January 31, 2025
    Use in toppical application

    Role of Artificial Intelligence in 3D Printing Personalized Medication

  • Sowmya V
    on
    December 13, 2019
    Nice keep it up

    Blood Test Might Predict Pregnancy Due Date and Preterm Birth

Find us on Facebook

Follow Us on Instagram

logo

Dui viverra Faucibus aliquet quis phasellus accumsan. Donec et facilisis sociosqu sed tortor elit eu aliquid turpis ridiculus.

Fly, shall, have greater fifth spirit midst under from stars thing is, had creepeth multiply kind. Man may they’re meat years have third bring replenish air two light deep fill.

About us

  • Dr.N.Sriram, Founder CEO, Pharmachronicles, HITS college of Pharmacy, Ghatkesar, Hyderabad, India
  • 9704361947
  • pharmachronicles@gmail.com
  • Recent

  • Popular

  • Comments

  • Resurgence of COVID-19 in Hong Kong and Singapore: A New Wave Driven by Waning Immunity ...

    By Pharmachronicles
    May 17, 2025
  • How Pharmacists Support Chronic Disease Management in the Community

    By Pharmachronicles
    May 9, 2025
  • OTC Medications: Safe Use, Common Mistakes, and Pharmacist Guidance

    By Pharmachronicles
    May 9, 2025
  • Pharmacovigilance Explained: Why Reporting Adverse Drug Reactions Saves Lives

    By Pharmachronicles
    May 7, 2025
  • pharmacy credit system

    Streamlining Salaries through Payment Credit System and Other Benefits for Pharmacy Professionals: Suggestive Measures for ...

    By Pharmachronicles
    February 1, 2025
  • Blood Test Might Predict Pregnancy Due Date and Preterm Birth

    By Sundari srinidhi
    December 12, 2019
  • Ai in 3D printing

    Role of Artificial Intelligence in 3D Printing Personalized Medication

    By Pharmachronicles
    January 29, 2025
  • FDA is carefully evaluating prescription opioid medications approved to treat cough in children

    By admin
    July 16, 2015
  • Pharmachronicles
    on
    February 27, 2025

    Streamlining Salaries through Payment Credit System and Other Benefits for Pharmacy Professionals: Suggestive Measures for PCI ...

    Thank you sir
  • G Krishna moorthy
    on
    February 1, 2025

    Streamlining Salaries through Payment Credit System and Other Benefits for Pharmacy Professionals: Suggestive Measures for PCI ...

    Good 👍 efforts Congratulations ...
  • Aarati sonawane
    on
    January 31, 2025

    Role of Artificial Intelligence in 3D Printing Personalized Medication

    Use in toppical application
  • Sowmya V
    on
    December 13, 2019

    Blood Test Might Predict Pregnancy Due Date and Preterm Birth

    Nice keep it up

Photostream

    Follow us

    • Contact
    • STUDENTS ZONE
    • About Us
    © Copyright Pharmachronicles. All rights reserved.